The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Gene therapy is advancing through approvals for particular diseases and carefully defined groups of patients—not as a single treatment or a general cure. Recent U.S. FDA decisions span viral gene delivery, cell-based treatments and CRISPR editing, while also highlighting the limits of the evidence, the risks of individual procedures and the need for follow-up.
What gene therapy means—and what it does not
The U.S. Food and Drug Administration defines gene therapy as administering genetic material to modify or manipulate gene expression, or to alter the biological properties of living cells, for therapeutic use. FDA considers human CRISPR/Cas9 genome editing to be gene therapy, too.
As an Amazon Associate I earn from qualifying purchases.
That definition covers treatments that work in different ways. Some deliver genetic material into the body using a viral vector, such as an adeno-associated virus (AAV). Others modify a patient’s cells outside the body and return them as a cellular product. Genome editing can change DNA at a targeted site; it is not the same process as delivering a functional gene copy. The label “gene therapy” therefore does not tell a patient how a treatment is given, what it changes or what risks to expect.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Approval is also specific: it applies to a named product for a defined indication and eligible population, based on particular evidence and a particular regulatory pathway. A diagnosis related to an approved therapy does not automatically make every patient eligible.
#1 Best Overall
How gene therapies work in practice
Delivering genetic material in the body
In an in vivo approach, a vector carries genetic material to cells in the patient. Itvisma, approved for spinal muscular atrophy (SMA), is an AAV-based therapy. Otarmeni, for certain inherited hearing loss, is also AAV-based and uses two AAV vectors. These products have different targets and indications; the shared vector family does not make them interchangeable.
Changing cells outside the body
In an ex vivo approach, cells are collected, modified or otherwise treated outside the patient, then administered back as a cellular product. Casgevy is a CRISPR-based treatment. Waskyra and Kresladi are approved as gene-modified cellular products for specific immune disorders. The cell collection, preparation and administration are part of the treatment—not a detail that can be inferred from the words “gene therapy.”
Rank #2
For any product, the useful comparison is its mechanism, target condition, eligibility rules, treatment process, evidence, follow-up and known risks. A broad category label cannot answer those questions.
Recent U.S. FDA approvals and expansions
The following milestones illustrate the range of indications and approaches. Approval dates and eligibility below reflect FDA decisions through October 7, 2026.
| Product and FDA action | Who the approval covers | What the FDA notice establishes |
|---|---|---|
| Itvisma (onasemnogene abeparvovec-brve) Approved November 24, 2025 |
Adults and children aged 2 years and older with SMA and a confirmed SMN1 mutation. | AAV-based gene therapy. FDA says most side effects are consistent with known Zolgensma risks; the approval notice discusses hepatotoxicity. |
| Waskyra (etuvetidigene autotemcel) Approved December 9, 2025 |
Pediatric patients aged 6 months and older and adults with Wiskott-Aldrich syndrome who meet the label’s transplant and donor criteria. | FDA describes two open-label studies and an expanded-access program totaling 27 patients. |
| Kresladi (marnetegragene autotemcel) Approved March 26, 2026 |
Pediatric patients with severe leukocyte adhesion deficiency type I (LAD-I), biallelic ITGB2 variants and no available HLA-matched sibling donor for allogeneic stem-cell transplant. | First FDA-approved gene therapy for severe LAD-I. Accelerated approval relied on biomarker increases with a sustained effect through month 24. |
| Otarmeni (lunsotogene parvec-cwha) Approved April 23, 2026 |
Pediatric and adult patients with severe-to-profound or profound hearing loss associated with biallelic OTOF variants. | Dual AAV-based therapy granted accelerated approval on the basis of one ongoing, multicenter, single-arm trial. Among 20 patients evaluable for efficacy, 80% experienced improved hearing. |
| Casgevy (exagamglogene autotemcel) Supplemental approval July 1, 2026 |
FDA extended eligibility to patients aged 2 years and older with specified sickle cell disease or transfusion-dependent beta thalassemia. | CRISPR-based treatment. The supplemental decision expanded the eligible population; it did not make the therapy suitable for every person with either diagnosis. |
The details in the table come from FDA product notices. In particular, Otarmeni’s 80% result is a reported outcome in the 20 patients evaluable for efficacy in its ongoing single-arm trial—not a comparison with another therapy or a guarantee of an individual patient’s result.
What approval evidence can—and cannot—tell you
Clinical evidence must be read product by product. The number and type of participants, study design, measured outcome and length of follow-up all affect what a result establishes. The figures above are not a basis for ranking treatments: the products address different conditions and populations, and their studies use different endpoints and designs.
Accelerated approval and continuing evidence
Accelerated approval is a specific regulatory pathway, not proof that every long-term benefit is already established. For Kresladi, FDA describes biomarker increases with a sustained effect through month 24 as the basis for approval. For Otarmeni, FDA based its decision on one ongoing, single-arm study and says continued approval may depend on confirming durable hearing improvement and assessing effects on speech development and quality of life. Those future outcomes are not the same as the hearing improvement observed in the initial efficacy group.
Free tools Windows power users keep installed
One-click scans. No signup required.
FDA guidance updated through 2026 addresses safety assessment for genome editing, clinical-trial design for small populations, manufacturing controls and collection of postapproval safety and efficacy information. FDA also describes a lifecycle-oriented approach to some chemistry, manufacturing and controls (CMC) requirements. These are continuing parts of development and oversight; the guidance alone does not establish how quickly a product can be manufactured or how accessible it will be to patients.
Best Value
Risks and treatment burden depend on the product
There is no single safety profile for all gene therapies. FDA’s Itvisma notice discusses hepatotoxicity and says most side effects are consistent with known Zolgensma risks. Otarmeni’s notice lists middle-ear infection, nausea, dizziness and procedural pain, and notes the need to monitor for surgical complications. Those are product-specific findings, not a list of risks that should be applied to every therapy.
Some products also involve substantial treatment procedures, such as cell collection and administration or surgery. Patients considering a particular therapy should review its current FDA labeling and discuss the eligibility criteria, treatment steps, monitoring, known risks and unresolved questions with their specialist. This overview is not individualized medical advice.
Why the field is gathering pace—but not delivering a universal cure
A 2026 review in Naunyn-Schmiedeberg’s Archives of Pharmacology counted four new cellular and gene therapy products approved by FDA in 2025. That is the review’s count across cellular and gene therapies, not a direct FDA year-by-year tally of gene therapies alone, and one year’s count does not establish a long-term growth rate.
The recent approvals nonetheless show a widening range of conditions and therapeutic approaches, from SMA and inherited hearing loss to rare immune disorders and blood diseases. Progress is accompanied by the practical and scientific work of establishing safety, designing trials for small patient populations, maintaining product quality and gathering evidence after approval. The FDA product list is a useful catalog, but it includes cellular therapies as well as gene therapies; a listed cell therapy should not be assumed to be gene therapy without checking how that product works.
Avoid do-it-yourself gene therapy products
FDA warns consumers about products intended for self-administration and DIY gene therapy kits. Its warning is explicit: “The sale of these products is against the law. FDA is concerned about the safety risks involved.” An FDA-approved treatment administered under medical care is not equivalent to an unapproved kit or a do-it-yourself procedure.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
